MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6
22 February 2024 - 9:00AM
MDxHealth to Present Fourth Quarter and
Full Year 2023 Financial Results and Corporate
Update on March 6
Company to Host Conference Call with Live
Q&A, March 6, 2024 at 4:30pm ET / 22:30 CET
IRVINE, CA, and HERSTAL,
BELGIUM – February 21, 2024 – MDxHealth SA (NASDAQ: MDXH),
a commercial-stage precision diagnostics company, today announced
it will release its financial results for the fourth quarter and
full year ended December 31, 2023, after market close on Wednesday,
March 6, 2024.
|
Title: |
MDxHealth Presents Fourth Quarter and Full Year 2023 Financial
Results and Corporate Update Conference Call and Webcast |
|
Speakers: |
Michael K. McGarrity, Chief Executive OfficerRon Kalfus, Chief
Financial Officer |
|
Date: |
March 6, 2024 |
|
Time: |
4:30pm ET/ 22:30 CET |
|
Conference Call Dial-in
Details: |
United States: 1-888-886-7786Belgium: 0800 76018The Netherlands:
0800 022 7908United Kingdom: 1-800-652-2435 |
|
Conference ID: |
80031769 |
|
Webcast: |
https://viavid.webcasts.com/starthere.jsp?ei=1655339&tp_key=a93e4440eb |
|
|
|
The webcast should be accessed 15 minutes prior to the
conference call start time. A replay of the webcast will be
available following the conclusion of the live call and will be
accessible on the Company’s website.
About mdxhealth
Mdxhealth is a commercial-stage precision
diagnostics company that provides actionable molecular information
to personalize patient diagnosis and treatment. The Company’s tests
are based on proprietary genomic, epigenetic (methylation) and
other molecular technologies and assist physicians with the
diagnosis and prognosis of urologic cancers and other urologic
diseases. For more information, visit mdxhealth.com and follow us
on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth
and linkedin.com/company/mdxhealth.
For more information:
info@mdxhealth.com
LifeSci Advisors (IR & PR)US: +1 949 271
9223
ir@mdxhealth.com
NOTE: The mdxhealth logo,
mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate
Score, GPS and Monitor mdx are trademarks or registered trademarks
of MDxHealth SA. The GPS test was formerly known as and is
frequently referenced in guidelines, coverage policies,
reimbursement decisions, manuscripts and other literature as
Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate
Score, and Oncotype Dx Prostate Cancer Assay, among others. The
Oncotype DX trademark, and all other trademarks and service marks,
are the property of their respective owners.
MDxHealth (NASDAQ:MDXH)
Historical Stock Chart
From Oct 2024 to Nov 2024
MDxHealth (NASDAQ:MDXH)
Historical Stock Chart
From Nov 2023 to Nov 2024
